caa a22 4500 378849492 CHVBK 20180305123320.0 cr unu---uuuuu 161128e20030919xx s 000 0 eng 10.1515/CCLM.2003.197 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.197 Two MMP-2 Promoter Polymorphisms (-790T/G and -735C/T) in Chronic Heart Failure [Elektronische Daten] [Anna Vašků, Monika Goldbergová, Lydie Izakovičová Hollá, Lenka Špinarová, Jindřich Špinar, Jiří Vítovec, Jiří Vácha] Remodelling of extracellular matrix by activated matrix metalloproteinases is considered to contribute to progression of ventricle remodelling during chronic heart failure. The aim of this study was to associate two promoter polymorphisms, -790T/G and -735C/T, in the gene for matrix metalloproteinase (MMP)-2 (gelatinase A) with chronic heart failure (CHF). For this purpose, 164 patients (124 men, 40 women, median age 56 years, range 21-91 years) with CHF (functional class NYHA II-IV, ejection fraction median 25%, cardiothoracic index more than 50%) were compared with 196 control subjects without clinical signs of cardiovascular disease (131 men and 65 women, median age 56 years, range 27-84 years) in -790T/G and -735C/T MMP-2 genotype distributions and allelic frequencies. The genotypes were determined by polymerase chain reaction (PCR) with restriction analyses. A significant increase of the T allele of the -790T/G MMP-2 polymorphism (p = 0.04), as well as of the C allele of the -735C/T MMP-2 gene polymorphism, in patients with CHF was proven (p = 0.04). The heterozygote CT of the 735C/T MMP-2 polymorphism exhibits a 7 times higher odds ratio (OR) for the CHF patients with lower levels of total cholesterol (less than 5 mmol/l), especially for nonhypertensive CHF men (OR = 7.28, 95% confidence interval 1.51-35.03, p = 0.006). Determination of MMP polymorphisms in the regulatory area of the gene could help us to comprehend individual susceptibility of patients with CHF to MMP inhibitors based on known risks of MMP genotypes. Clin Chem Lab Med 2003; 41(10):12991303 Copyright © 2003 by Walter de Gruyter GmbH & Co. KG Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence Vašků Anna aut Goldbergová Monika aut Hollá Lydie Izakovičová aut Špinarová Lenka aut Špinar Jindřich aut Vítovec Jiří aut Vácha Jiří aut Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/10(2003-09-19), 1299-1303 1434-6621 41:10<1299 2003 41 cclm https://doi.org/10.1515/CCLM.2003.197 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2003.197 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vašků Anna aut NATIONALLICENCE 700 1- Goldbergová Monika aut NATIONALLICENCE 700 1- Hollá Lydie Izakovičová aut NATIONALLICENCE 700 1- Špinarová Lenka aut NATIONALLICENCE 700 1- Špinar Jindřich aut NATIONALLICENCE 700 1- Vítovec Jiří aut NATIONALLICENCE 700 1- Vácha Jiří aut NATIONALLICENCE 773 0- Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/10(2003-09-19), 1299-1303 1434-6621 41:10<1299 2003 41 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter